Roche launched a new test to detect sexually transmitted infections as part of its cobas 6800/8800 systems in markets accepting the CE mark.

Researchers at Johns Hopkins have developed a noninvasive blood test that can detect signs of eight different types of cancer before symptoms begin.

Illumina, the maker of DNA sequencers, unveiled its latest device with a price tag of just under $20,000.

The project will see Regeneron sequence the exomes of 500,000 Britons with the financial backing of AbbVie, Alnylam, AstraZeneca, Biogen and Pfizer.

In looking ahead, we have picked two of the ways companies are working to change healthcare and the cybercrime fly in the ointment for analysis.

Array and Pfizer's initial focus is to test drug combos in a phase 1b trial in non-small cell lung cancer and pancreatic cancer.

The agreement positions Cochlear to expand beyond hearing-loss devices by licensing the therapeutic if it impresses in development.

The agreement supports Roche’s drive to develop IHC assays that enable doctors to identify patients with NTRK gene rearrangements.